03/27/2025
5:17 PM | Samsara BioCapital, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13D/A | |
03/14/2025
3:43 PM | Fanucci Marsha (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
4:46 PM | Syros Pharmaceuticals (Subject)
WIRTH PETER (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/10/2025
3:27 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
Get the Latest News and Ratings for SYRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/10/2025
3:29 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:31 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:21 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:21 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
02/14/2025
9:10 AM | Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
7:41 AM | Deep Track Capital, LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/12/2025
8:41 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
01/16/2025
3:49 PM | Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025
3:01 PM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/30/2024
4:11 PM | AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/27/2024
3:02 PM | Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/13/2024
3:17 PM | Flagship VentureLabs IV, LLC (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
2:01 PM | Syros Pharmaceuticals (Subject)
Young Richard A (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2024
6:00 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/25/2024
4:59 PM | Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
4:22 PM | Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
4:42 PM | Roth David (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
5:00 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
4:20 PM | Stephens Kristin (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
3:45 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
3:18 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
11:08 AM | Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
6:01 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
4:24 PM | Bain Capital Life Sciences Fund II, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/14/2024
4:28 PM | Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/13/2024
6:00 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/04/2024
4:00 PM | Stephens Kristin (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad) Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade.
In 2023, it surged 239%. And in 2024, it soared another 171% on the year…
But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less? Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. |
11/04/2024
4:01 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/31/2024
5:49 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/02/2024
4:00 PM | Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
4:00 PM | Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
4:00 PM | AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
4:00 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
4:00 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
6:01 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2024
4:03 PM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/02/2024
5:39 PM | Invus Global Management, LLC (Filed by)
Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
07/31/2024
6:44 AM | Syros Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
07/31/2024
5:55 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
06/07/2024
3:30 PM | Syros Pharmaceuticals (Issuer)
WIRTH PETER (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Fanucci Marsha (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | OH ANDREW M. (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Eckhardt Sue Gail (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Dunsire Deborah (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Syros Pharmaceuticals (Issuer)
TYSON TIMOTHY (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:30 PM | Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2024
3:30 PM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/04/2024
3:41 PM | AKKARAJU SRINIVAS (Reporting)
AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2024
5:42 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
Buy SYRS Stock Free SYRS Stock Alerts